The Risk of Cancer in Patients with Generalized Anxiety Disorder: A Nationwide Population-Based Study

Cheng-Che Shen\textsuperscript{1,9}, Yu-Wen Hu\textsuperscript{2,3,4,9}, Li-Yu Hu\textsuperscript{5}, Man-Hsin Hung\textsuperscript{6}, Tung-Ping Su\textsuperscript{2,7}, Min-Wei Huang\textsuperscript{1}, Chia-Fen Tsai\textsuperscript{2,7}, Shuo-Ming Ou\textsuperscript{8}, Sang-Hue Yen\textsuperscript{2,3,9}, Cheng-Huai Tzeng\textsuperscript{2,6}, Tzeon-Jye Chiou\textsuperscript{2,6}, Tseng-Ji Chen\textsuperscript{10}, Chia-Jen Liu\textsuperscript{2,4,6,11}*

\textsuperscript{1}Department of Psychiatry, Chiayi Branch, Taichung Veterans General Hospital, Chiayi, Taiwan, \textsuperscript{2}School of Medicine, National Yang-Ming University, Taipei, Taiwan, \textsuperscript{3}Department of Psychiatry, Yuli Veterans Hospital, Hualien, Taiwan, \textsuperscript{4}Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, \textsuperscript{5}Department of Psychiatry, National Yang-Ming University Hospital, Yilan, Taiwan, \textsuperscript{6}Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, \textsuperscript{7}Department of Health and managed by the National Health Research Institutes, \textsuperscript{8}Department of Internal Medicine, National Yang-Ming University Hospital, Yilan, Taiwan, \textsuperscript{9}Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan, \textsuperscript{10}Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, \textsuperscript{11}Department of Psychiatry, Chiayi Branch, Taichung Veterans General Hospital, Chiayi, Taiwan.

Abstract

Objective: To evaluate the risk of cancer among patients with generalized anxiety disorder (GAD) in a nationwide population-based dataset.

Methods: We recruited newly-diagnosed GAD patients aged 20 years or older without antecedent cancer from the Taiwan National Health Insurance Research database between 2000–2010. Standardized incidence ratios (SIRs) of cancers were calculated in GAD patients, and the subgroup of GAD patients diagnosed by psychiatric specialists.

Results: A total of 559 cancers developed among 19,793 GAD patients with a follow-up of 89,485 person-years (median follow-up of 4.34 years), leading to a significantly increased SIR of 1.14 [95% confidence interval (CI) 1.05–1.24]. Male GAD patients had a significantly increased SIR overall (1.30, 95% CI 1.15–1.46) and for lung and prostate cancer (1.77, 95% CI 1.56–2.93, respectively). Patients over 80 years of age also had a significantly increased SIR (1.56, 95% CI 1.25–1.92), especially in males. However, psychiatrist-diagnosed GAD patients did not show increased cancer risk relative to the general population, perhaps due to having fewer physical comorbidities than non-psychiatrist-diagnosed GAD patients.

Conclusion: This study found that overall cancer risk is elevated among patients with GAD. The risk of lung and prostate cancer also increased in male patients with GAD. This increased cancer risk may be due to physical comorbidities and surveillance bias. Further prospective study is necessary to confirm these findings.

Citation: Shen C-C, Hu Y-W, Hu L-Y, Hung M-H, Su T-P, et al. (2013) The Risk of Cancer in Patients with Generalized Anxiety Disorder: A Nationwide Population-Based Study. PLoS ONE 8(2): e57399. doi:10.1371/journal.pone.0057399

Editor: Andrew H. Kemp, University of Sydney, Australia

Received November 15, 2012; Accepted January 18, 2013; Published February 27, 2013

Copyright: © 2013 Shen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by the National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health or National Health Research Institutes. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: chiajenliu@gmail.com

† These authors contributed equally to this work.

Introduction

Generalized anxiety disorder (GAD) is one of the most common anxiety disorders among the general population. It is characterized by persistent and excess worrying, sleep disturbance, muscle tension and being easily fatigued. [1] According to two major studies in the United States, the Epidemiological Catchment Area study and the National Comorbidity Survey study, the estimated lifetime prevalence rate for GAD is 4.1–6.6%. [2,3] In a large cohort study in Germany, the 12-month prevalence rate of GAD in the community was 3.0%. [4].

Despite the availability of several treatment options, GAD remains a major public health concern. It is consistently associated with considerable disability and overutilization of medical services. [5] GAD has a detrimental impact on patients’ work, education, social relationships and quality of life. [6,7] It is also associated with negative health outcomes, such as increased risk for cardiovascular events and premature death in patients with chronic obstructive pulmonary disease (COPD). [8–11] Therefore, GAD incurs considerable costs due to healthcare expenses and loss of productivity. [12].

Psychological distress, such as ongoing depression and anxiety-related symptomatology, has been associated with poorer survival rate of cancer patients. [13,14] However, whether psychological factors increase the incidence of cancer is unclear. Numerous
papers in the literature investigated associations between cancer incidence and psychosocial factors, such as anxiety, personality and depression. However, the results are controversial, [14–24] and few of these studies focused on anxiety or anxiety disorders. [20–22] A study in Taiwan found that patients with anxiety disorders had an increased risk of developing prostate cancer, a marginally decreased risk of cervical cancer, but no increase in overall cancer risk. [20] In addition, a study in the UK showed that patients with anxiety disorders had higher risks for lung and brain cancer, but no increase in overall cancer risk. [21].

The aim of the current study was to determine whether GAD is associated with an increased risk of cancer. This study was a population-based retrospective cohort study using a database derived from the National Health Insurance (NHI) system in Taiwan.

Materials and Methods

Data Sources
The NHI program, which began in 1995, is a mandatory universal health insurance program, offering comprehensive medical care coverage to all Taiwanese residents with a coverage rate of up to 98%. [25,26] It includes coverage for outpatient, inpatient, emergency, dental, and traditional Chinese medicine services, as well as prescription drugs. This study used the NHI research database, which is managed and made available to the public by the National Health Research Institute (NHRI) of Taiwan. The NHI database of catastrophic illness provides comprehensive enrollment information for all patients with severe diseases, such as cancer, who have received copayment exemption under the NHI program. Confidentiality is maintained according to the data regulations of the Bureau of National Health Insurance and the NHRI. This study was exempt from full review by the institutional review board, as the NHI dataset consists of de-identified secondary data for research purposes.

Study Population
We conducted a retrospective cohort study from January 1, 1996 to December 31, 2010. Newly-diagnosed patients with GAD were selected from January 1, 2000 to December 31, 2009. This study recruited patients aged 20 years or older at the time of GAD diagnosis who had no prior malignancies. GAD was defined according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 300.02.

Statistical Analyses
The main dependent variable was occurrence of cancer, as reported in the Registry for Catastrophic Illness. For a diagnosis of cancer to be reported in the Registry, histological confirmation is required. GAD patients were followed until development of cancer, death, dropout from the NHI program, or the end of the year 2010.

The risk of cancer among the GAD cohort was determined using a standardized incidence ratio (SIR), which is defined as the observed number of cancer occurrences divided by the expected number. The expected number of cancers was calculated by multiplying the national incidence rate of cancers, stratified by gender, calendar year, and age in 5-year intervals, by the corresponding stratum-specific person-time accrued in the cohort. The incidence rates of cancers among the general population were obtained from the Taiwan Cancer Registry. The 95% confidence intervals (CIs) for the SIRs were estimated under the assumption that the number of cancers followed a Poisson probability distribution. We determined the SIRs for subgroups for gender and age. To investigate potential surveillance bias and the possibility of GAD as a paraneoplastic phenomenon, subgroups were stratified by the duration since GAD diagnosis. SIRs were also estimated for each cancer type. Finally, SIRs for the subgroup of GAD patients diagnosed by psychiatric specialists were determined. Age at diagnosis and prevalence of physical comorbidities before GAD diagnosis were also analyzed. Categorical variables were compared using chi-square tests, and continuous variables were compared using t-tests.

Data extraction and computations were performed using the Perl programming language (version 5.12.2). Microsoft SQL Server 2005 (Microsoft Corp., Redmond, WA, USA) was used for data linkage, processing, and sampling. All statistical analyses were performed using SPSS statistical software version 17.0 for Windows (SPSS, Inc., Chicago, Illinois). Statistical significance was defined as a p value of less than 0.05.

Results

Patient Demographics
Overall, the cohort was observed for 89,485 person-years from 2000–2010. A total of 19,793 patients with GAD (64.4% female) were identified. The mean age at diagnosis was 49.6 years (standard deviation, 15.7 years), and the median follow-up period was 4.34 years (interquartile range, 2.1–6.8 years). Patient demographics are shown in Table 1.

All Cancers
A total of 559 cancers occurred within the observation period. Compared with the general population, patients with GAD had an increased overall cancer risk with an SIR of 1.14 (95% CI 1.05–1.24). A subgroup analysis for gender showed that males had an increased SIR (1.30, 95% CI 1.15–1.46, p<0.001), but females did not (1.02, 95% CI 0.91–1.15). A subgroup analysis for age showed that patients aged 80 years and older had an increased SIR (1.56, 95% CI 1.25–1.92, p<0.001), but those under 80 did not. Males over 80 years of age showed the highest SIR (1.82, 95% CI 1.35–2.39, p<0.001). Within the first year of GAD diagnosis, 111 cancers occurred with an SIR of 1.22 (95% CI 1.01–1.47, p=0.044). If the first year was excluded, the SIR remained significantly elevated at 1.12 (95% CI 1.02–1.23, p=0.015). The results of the subgroup analysis are summarized in Table 2.

Specific Cancer Types
The cancer types most commonly observed in the GAD cohort were lung and mediastinum (n=90), followed by liver and biliary tract (n=82), then colon and rectum (n=79). An increased SIR was observed for lung and mediastinum (1.53, 95% CI 1.23–1.88, p<0.001) and prostate cancers (2.17, 95% CI 1.56–2.93, p<0.001) in GAD patients. However, the increased SIR of lung and mediastinum was observed only in male patients (1.77, 95% CI 1.33–2.30, p<0.001), but not in females (1.27, 95% CI 0.88–1.76). SIRs for specific types of cancers are presented in Table 3. If the person-time of the first year was excluded, SIRs of lung cancer (1.49, 95% CI 1.16–1.89, p=0.002) and prostate cancer (2.24, 95% CI 1.57–3.10, p<0.001) remained significantly elevated. Excluding patients with prostate or lung cancer did not increase the risks for other types of cancers in the total GAD cohort (1.04, 95% CI 0.94–1.14) or in the subgroup of males with GAD (1.10, 95% CI 0.95–1.28).

GAD Patients Diagnosed by Psychiatric Specialists
The results for GAD patients diagnosed by psychiatric specialists are shown in Tables 4–5, including SIRs according to
Table 1. Characteristics of patients with generalized anxiety disorder.

| Total | Male | Female |
|-------|------|--------|
| No. of patients | 19793 | 7041 | 12752 |
| Person-years at risk | 89464.9 | 31437.3 | 58027.6 |
| Median follow-up, years (interquartile range) | 4.3 (2.1–6.8) | 4.3 (2.1–6.7) | 4.4 (2.2–6.8) |
| Mean age at diagnosis (± SD), years | 49.6 (± 15.7) | 49.9 (± 16.3) | 49.5 (± 15.4) |

| Distribution of patients according to age | |
|---|---|---|
| 20–39 | 5832 | 2159 | 3673 |
| 40–59 | 8748 | 2887 | 5861 |
| 60–79 | 4654 | 1754 | 2900 |
| ≥80 | 559 | 241 | 318 |

Table 2. Standardized incidence ratios (SIRs) according to age, gender and duration of generalized anxiety disorder.

| Characteristics | Total | Male | Female |
|----------------|-------|------|--------|
| All cancers | 559 | 489.07 | 1.14 (1.05–1.24) | 274 | 210.65 | 1.30 (1.15–1.46) |
| Age, years | | | | | | |
| 20–39 | 24 | 19.18 | 1.25 (0.80–1.86) | 10 | 5.91 | 1.69 (0.81–3.11) |
| 40–59 | 167 | 163.89 | 1.02 (0.87–1.19) | 64 | 54.70 | 1.17 (0.90–1.49) |
| 60–79 | 282 | 250.77 | 1.12 (1.00–1.26) | 149 | 121.96 | 1.22 (1.03–1.43) |
| ≥80 | 86 | 55.23 | 1.56 (1.25–1.92) | 51 | 28.09 | 1.82 (1.35–2.39) |
| Duration | | | | | | |
| 0–1 | 111 | 90.83 | 1.22 (1.01–1.47) | 53 | 39.07 | 1.36 (1.02–1.77) |
| ≥1 | 448 | 398.25 | 1.12 (1.02–1.23) | 221 | 171.58 | 1.29 (1.12–1.47) |
| 1–5 | 309 | 275.93 | 1.12 (1.00–1.25) | 154 | 118.78 | 1.30 (1.10–1.52) |
| ≥5 | 139 | 122.31 | 1.14 (0.96–1.34) | 67 | 52.81 | 1.27 (0.98–1.61) |

GAD and Cancer Risk

Discussion

To the best of our knowledge, this is the first large population-based study to evaluate the risk of cancer among patients with GAD. This study included 19,793 patients with a follow-up of 89,485 person-years. The data showed an increased overall cancer risk in GAD patients (SIR 1.14) relative to the general population, especially males and patients aged 80 years and older. Specifically, the risks of lung and prostate cancer were increased in male patients. It is interesting to note that cancer risk was not elevated in psychiatrist-diagnosed GAD patients.

The current study design included unbiased subject selection and SIR estimations with matching for age, gender, and calendar year. Because participation in the NHI is mandatory and all residents of Taiwan can access healthcare with low co-payments, referral bias is essentially removed and follow-up is complete. To apply for a cancer catastrophic illness certificate, pathologic proof of malignancy is mandatory, and laboratory and imaging studies should also be provided. Patients with a certificate of catastrophic illness can be exempted from related medical expenses, especially hospital costs. Therefore, cancer diagnoses in this study were not only reliable, but also exhaustive.

While some large retrospective studies have investigated the association between anxiety and cancer risk, their results were inconsistent. [20–22] A study of 24,066 patients in Taiwan with a follow-up of 193,207 person-years reported an increased risk of developing prostate cancer and a marginally decreased risk of cervical cancer, but no increase in overall cancer risk. [20] In addition, a study of 24,290 patients in the UK showed higher risks for lung and brain cancer, but no increase in overall cancer risk. [21] A prospective study of 10,892 women in Finland with a follow-up of 6–9 years showed that anxiety was not a risk factor for breast cancer. [22] These divergent results may be due to different definitions of anxiety and inclusion criteria. The Taiwan study included patients with GAD, panic disorder, agoraphobia, social...
| Table 3. Standardized incidence ratios (SIRs) for specific cancer types among patients with generalized anxiety disorder. |
|---------------------------------|-----------|-------------|-------------|-----------|-------------|-------------|
| **Site of cancers** | **Total** | **Male** | **Female** | **Total** | **Male** | **Female** |
|----------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| All cancers          | 559       | 489.07    | 1.14(1.05–1.24) | 274       | 210.65    | 1.30(1.15–1.46) |
| Head and neck        | 30        | 37.01     | 0.81(0.55–1.16) | 24        | 28.79     | 0.83(0.53–1.24) |
| Digestive            | 204       | 181.31    | 1.13(0.98–1.29) | 108       | 92.81     | 1.16(0.95–1.40) |
| Esophagus            | 5         | 8.36      | 0.60(0.19–1.40) | 5         | 7.26      | 0.69(0.22–1.61) |
| Stomach              | 30        | 24.08     | 1.25(0.84–1.78) | 17        | 12.50     | 1.36(0.79–2.18) |
| Colon and rectum     | 79        | 71.31     | 1.11(0.88–1.38) | 38        | 31.19     | 1.22(0.86–1.67) |
| Liver and biliary tract | 82       | 68.25     | 1.20(0.96–1.49) | 45        | 37.82     | 1.19(0.87–1.59) |
| Pancreas             | 8         | 8.79      | 0.91(0.39–1.79) | 3         | 3.87      | 0.78(0.16–2.27) |
| Lung and mediastinum | 90        | 58.75     | 1.53(1.23–1.88) | 55        | 31.09     | 1.77(1.33–2.30) |
| Bone and Soft tissue | 7         | 3.79      | 1.85(0.74–3.80) | 5         | 1.73      | 2.90(0.94–6.76) |
| Skin                 | 8         | 9.57      | 0.84(0.36–1.65) | 3         | 3.88      | 0.77(0.16–2.26) |
| Breast               | 55        | 64.59     | 0.85(0.64–1.11) | 1         | 0.23      | 4.38(0.11–24.40) |
| Genitourinary        | 106       | 83.54     | 1.27(1.04–1.53) | 57        | 33.55     | 1.70(1.29–2.20) |
| Cervix               | 17        | 18.18     | 0.93(0.54–1.50) | 17        | 18.18     | 0.93(0.54–1.50) |
| Uterus               | 10        | 9.54      | 1.05(0.50–1.93) | –         | –         | –         |
| Ovary                | 6         | 8.14      | 0.74(0.27–1.60) | –         | –         | –         |
| Prostate             | 42        | 19.38     | 2.17(1.56–2.93) | 42        | 19.38     | 2.17(1.56–2.93) |
| Bladder              | 12        | 15.29     | 0.79(0.41–1.37) | 9         | 9.06      | 0.99(0.45–1.89) |
| Kidney               | 19        | 13.01     | 1.46(0.88–2.28) | 6         | 5.11      | 1.70(0.43–2.56) |
| Thyroid              | 16        | 11.38     | 1.41(0.80–2.28) | 2         | 1.50      | 1.33(0.46–4.81) |
| Hematologic malignancies | 26    | 20.67     | 1.26(0.82–1.84) | 12        | 9.23      | 1.30(0.67–2.27) |
| All Others           | 17        | 18.45     | 0.92(0.54–1.47) | 7         | 7.83      | 0.89(0.36–1.84) |

SIR Standardized incidence ratio; CI confidence interval.

doi:10.1371/journal.pone.0057399.t003

| Table 4. Standardized incidence ratios (SIRs) according to age, gender and duration of psychiatrist-diagnosed generalized anxiety disorder. |
|---------------------------------|-----------|-------------|-----------|-----------|-------------|-------------|
| **Characteristics** | **Total** | **Male** | **Female** | **Total** | **Male** | **Female** |
|----------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| All cancers          | 123       | 118.08    | 1.04(0.87–1.24) | 53        | 52.70     | 1.01(0.75–1.32) |
| Age, years           |           |           |           |           |           |           |
| 20–39                | 6         | 7.38      | 0.81(0.30–1.77) | 1         | 2.41      | 0.42(0.01–2.31) |
| 40–59                | 43        | 46.83     | 0.92(0.66–1.24) | 15        | 17.06     | 0.88(0.49–1.45) |
| 60–79                | 57        | 53.21     | 1.07(0.81–1.39) | 27        | 27.09     | 1.00(0.66–1.45) |
| ≥80                  | 17        | 10.66     | 1.59(0.93–2.55) | 10        | 6.14      | 1.63(0.78–3.00) |
| Duration             |           |           |           |           |           |           |
| 0–1                  | 24        | 22.29     | 1.08(0.69–1.60) | 14        | 9.77      | 1.43(0.78–2.41) |
| ≥1                   | 99        | 95.79     | 1.03(0.84–1.26) | 39        | 42.93     | 0.91(0.65–1.24) |
| 1–5                  | 70        | 66.82     | 1.05(0.82–1.32) | 26        | 29.80     | 0.87(0.57–1.28) |
| ≥5                   | 29        | 28.97     | 1.00(0.67–1.44) | 13        | 13.14     | 0.99(0.53–1.69) |

SIR Standardized incidence ratio; CI confidence interval.

doi:10.1371/journal.pone.0057399.t004
| Site of cancers          | Total | Male | Female |
|-------------------------|-------|------|--------|
|                         | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) |
| All cancers             | 123 | 118.08 | 1.04(0.87–1.24) | 53 | 52.70 | 1.01(0.75–1.32) | 70 | 65.38 | 1.07(0.83–1.35) |
| Head and neck           | 9 | 10.31 | 0.87(0.40–1.66) | 7 | 8.27 | 0.85(0.34–1.74) | 2 | 2.03 | 0.98(0.12–3.55) |
| Digestive               | 35 | 42.06 | 0.83(0.58–1.16) | 20 | 23.09 | 0.87(0.53–1.34) | 15 | 18.97 | 0.79(0.44–1.30) |
| Esophagus               | 1 | 2.18 | 0.46(0.01–2.56) | 1 | 1.94 | 0.51(0.01–2.87) | 0 | 0.23 | 0.00(0.00–15.94) |
| Stomach                 | 6 | 5.49 | 1.09(0.40–2.38) | 5 | 2.97 | 1.68(0.55–3.93) | 1 | 2.52 | 0.40(0.01–2.21) |
| Colon and rectum        | 11 | 16.31 | 0.67(0.34–1.21) | 5 | 7.58 | 0.66(0.21–1.54) | 6 | 8.73 | 0.69(0.25–1.50) |
| Anus                    | 0 | 0.12 | 0.00(0.00–31.47) | 0 | 0.04 | 0.00(0.00–87.66) | 0 | 0.08 | 0.00(0.00–49.08) |
| Liver and biliary tract | 15 | 16.01 | 0.94(0.52–1.55) | 8 | 9.62 | 0.83(0.36–1.64) | 7 | 6.39 | 1.10(0.44–2.26) |
| Pancreas                | 2 | 1.97 | 1.02(0.12–3.67) | 1 | 0.94 | 1.07(0.03–5.94) | 1 | 1.03 | 0.97(0.02–5.41) |
| Lung and mediastinum    | 19 | 13.30 | 1.43(0.86–2.23) | 11 | 7.30 | 1.51(0.75–2.70) | 8 | 6.00 | 1.33(0.58–2.63) |
| Bone and Soft tissue    | 2 | 0.98 | 2.05(0.25–7.40) | 2 | 0.46 | 4.31(0.52–15.57) | 0 | 0.51 | 0.00(0.00–7.20) |
| Skin                    | 1 | 2.13 | 0.47(0.01–2.61) | 0 | 0.94 | 0.00(0.00–3.94) | 1 | 1.20 | 0.84(0.02–4.66) |
| Breast                  | 22 | 16.89 | 1.30(0.82–1.97) | 1 | 0.06 | 17.69(0.45–98.54) | 21 | 16.83 | 1.25(0.77–1.91) |
| Genitourinary           | 26 | 19.72 | 1.32(0.86–1.93) | 10 | 7.73 | 1.29(0.62–2.38) | 16 | 11.99 | 1.33(0.76–1.71) |
| Cervix                  | 5 | 4.39 | 1.14(0.37–2.66) | – | – | – | 5 | 4.39 | 1.14(0.37–2.66) |
| Uterus                  | 4 | 2.48 | 1.61(0.44–4.13) | – | – | – | 4 | 2.48 | 1.61(0.44–4.13) |
| Ovary                   | 3 | 2.14 | 1.40(0.29–4.10) | – | – | – | 3 | 2.14 | 1.40(0.29–4.10) |
| Prostate                | 9 | 4.31 | 2.09(0.95–3.96) | 9 | 4.31 | 2.09(0.95–3.96) | – | – | – |
| Bladder                 | 0 | 3.45 | 0.00(0.00–1.07) | 0 | 2.16 | 0.00(0.00–1.71) | 0 | 1.30 | 0.00(0.00–2.84) |
| Kidney                  | 5 | 2.95 | 1.70(0.55–3.96) | 1 | 1.26 | 0.79(0.42–4.41) | 4 | 1.68 | 2.38(0.65–6.09) |
| Thyroid                 | 2 | 3.23 | 0.62(0.07–2.24) | 0 | 0.45 | 0.00(0.00–8.13) | 2 | 2.78 | 0.72(0.09–2.60) |
| Hematologic malignancies | 3 | 5.02 | 0.60(0.12–1.75) | 2 | 2.36 | 0.85(0.10–3.06) | 1 | 2.66 | 0.38(0.01–2.09) |
| All Others              | 4 | 4.45 | 0.90(0.25–2.30) | 0 | 2.04 | 0.00(0.00–1.81) | 4 | 2.40 | 1.66(0.45–4.26) |

SIR: Standardized incidence ratio; CI: confidence interval.
doi:10.1371/journal.pone.0057399.t005

| Site of cancers          | Total | Male | Female |
|-------------------------|-------|------|--------|
|                         | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) |
| All cancers             | 2272 | 4769 | 3750 | 9002 |
| Age at diagnosis(±SD)   | 45.9(±15.8) | 51.8(±16.2) | <0.001 | 45.7(±15.0) | 51.1(±15.3) | <0.001 |
| Comorbidities, n(%)     | Diabetes mellitus | 380(16.7) | 1015(21.3) | <0.001 | 622(16.6) | 1877(20.9) | <0.001 |
|                        | Dyslipidemia | 593(26.1) | 1542(32.3) | <0.001 | 978(26.1) | 2803(31.1) | <0.001 |
|                        | Hypertension | 685(30.1) | 2027(42.5) | <0.001 | 1012(27.0) | 3550(39.4) | <0.001 |
|                        | Ischemic heart disease | 498(21.9) | 1494(31.3) | <0.001 | 743(19.8) | 2657(29.5) | <0.001 |
|                        | Heart failure | 113(5.0) | 479(10.0) | <0.001 | 184(4.9) | 843(9.4) | <0.001 |
|                        | Cerebrovascular disease | 305(13.4) | 925(19.4) | <0.001 | 464(12.4) | 1454(16.2) | <0.001 |
|                        | COPD | 500(22.0) | 1411(29.6) | <0.001 | 711(19.0) | 2027(22.5) | <0.001 |
|                        | Cirrhosis | 672(29.2) | 152(3.2) | 0.590 | 65(1.7) | 154(1.7) | 0.929 |

SD: standard deviation; COPD: chronic obstructive pulmonary disease.
doi:10.1371/journal.pone.0057399.t006
phobia, post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD), selecting only subjects who had been admitted at least three times. These inclusion criteria may have predominately selected patients with severe illness and certain types of anxiety disorders, such as PTSD and OCD, as most GAD patients are treated in outpatient settings. [12] Similarly, the UK study might have also assessed severely ill patients, as it included patients who were admitted with ICD-9 code 300 (anxiety, dissociative and somatoform disorders), ICD-8 code 300 (neurosis), ICD-7 code 310 (anxiety reaction without mention of somatic symptoms), or ICD-10 code F41 (other anxiety disorders, including panic disorder without agoraphobia, generalized anxiety disorder, other mixed anxiety disorders, other specified anxiety disorders, and anxiety disorder, unspecified). In addition, the use of different ICD systems and several ICD codes made the study group heterogeneous. In the Finland study, anxiety was evaluated by the Spielberger State-Trait Anxiety Inventory, rather than physician diagnosis. Thus, the inconsistency of results across these studies could be due to different definitions of anxiety and inclusion criteria. The current study had a more homogenous population, consisting of only GAD patients.

The current study found that overall cancer risk in GAD patients was higher than the general population with an SIR of 1.14. It has been hypothesized that psychological factors including anxiety could impair immune and endocrine function. [27,28] Anxiety activates the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic-adrenal-medullary axis, elevating corticosterone and other stress hormones, such as catecholamines. These hormones could modulate the activity of the tumor microenvironment. [29] Many studies have shown that stress can affect the cellular process involved in the repair of damaged DNA, [30] which could facilitate development of oncogenic mutations. Stress hormones could also accelerate growth of tumor cells by altering glucose uptake, [31] promote tumor migration by increasing the expression of matrix metalloproteinase-2, [32] and stimulate angiogenesis by inducing production of pro-angiogenic cytokines, such as vascular endothelial growth factor and interleukin-6. [29] These mechanisms might contribute differentially to specific stages of cancer development and to certain cancer types. However, the median follow-up in the current study was 4.34 years, which may have been too short to detect increased risk of some malignancies, especially for cancers with long latency periods.

In the present study, incident cancers were increased in the first year after diagnosis of GAD with an SIR of 1.22. One possible explanation for this result is surveillance bias. [33] Patients with GAD are likely to have more outpatient visits and thus more medical examinations than the general population, which leads to an earlier diagnosis of cancer. In addition, the close temporal relationship between diagnosis of GAD and cancer could support anxiety as a paraneoplastic manifestation in patients with undiagnosed malignancy. [34,35] While excluding data from patients for whom GAD and cancer were diagnosed within one year decreased the SIR to 1.12, it remained significantly elevated relative to the general population. Hence, it seems reasonable to conclude that increased cancer risk in GAD patients in the current study was not due only to surveillance bias or a paraneoplastic manifestation.

The current study also found an increased SIR of 1.56 in GAD patients aged 80 and older, especially in males. Given that the risk of prostate cancer was also increased significantly, it is reasonable to infer that such increased SIR was due mainly to prostate cancer, which is commonly diagnosed in advanced age. [36,37] Because prostate cancer usually has an indolent course and can be detected by rectal examination and a prostate specific antigen (PSA) test, it is prone to surveillance bias. The Taiwan study showed that a higher proportion of patients with anxiety disorder underwent a PSA test, and they had a higher risk of prostate cancer. [20] Therefore, the increased risk of prostate cancer in patients with anxiety disorders may be mainly due to surveillance bias. However, SIRs of prostate cancer were still increased when the person-time of the first year was excluded, suggesting a relationship between GAD and prostate cancer. One possible explanation for the increased risk of prostate cancer in GAD patients is that obesity, lack of exercise, and high blood pressure are more frequent in patients with anxiety disorders than in the general population, [8,38,39] and these characteristics increase the risk of prostate cancer. [40–42].

The current study found an increased risk of lung cancer in male patients. Smoking is a possible confounder, as GAD is associated with heavy smoking, nicotine dependence, and smoking cessation failure, and smoking itself is a major risk factor for lung cancer. [43–45] However, the risks of other smoking-related malignancies, such as head and neck cancer, esophageal cancer and bladder cancer, were not increased in the study cohort. Another possible explanation for the increased risk of lung cancer in GAD patients could be that patients with lung diseases, such as COPD, are prone to anxiety, [11] and these lung diseases themselves are risk factors for lung cancer. [46]. Furthermore, these lung diseases have a higher incidence in males, [47–49] which could explain why increased lung cancer risk was noted in male GAD patients, but not females.

While the overall GAD cohort had an increased risk of cancer, prostate cancer, and lung cancer, no change in risk was observed in the subgroup of psychiatrist-diagnosed GAD patients. This inconsistency might be due to a smaller number of patients in the psychiatrist-diagnosed cohort, which decreased statistical power for this group. Furthermore, as shown in Table 6, non-psychiatrist-diagnosed GAD patients had more physical comorbidities, such as COPD. Many physical comorbidities have been demonstrated to increase cancer risk. [46,50,51] For example, COPD is a risk factor for lung cancer. Therefore, the increased risk of lung cancer in GAD patients could be due to physical comorbidities, such as COPD.

There are several limitations to this large population-based study. First, many demographic variables were not available, such as family history of cancer, environmental exposures, diet, cigarette smoking, and alcohol use. Second, the diagnostic accuracy and severity of GAD could not be obtained. Whether the severity of GAD is a related to cancer development should be further evaluated. Third, this study did not assess the effect of psychotropic on cancer risk. Antipsychotics and benzodiazepines are two main treatments for GAD. Antipsychotics have been hypothesized to account for reduced cancer risk in schizophrenia patients, and benzodiazepines have been proposed to increase cancer risk. [52,53] Finally, the follow-up duration of the current study might be too short to detect carcinogenesis of certain types of cancers.

In conclusion, this population-based retrospective cohort study found increased cancer risk among patients with GAD, especially males, compared with the general population. Specifically, the risks of prostate and lung cancers among male GAD patients were significantly increased. However, cancer risk did not increase in psychiatrist-diagnosed GAD patients. Increased cancer risk in GAD patients may be due to physical comorbidities and surveillance bias. Further large, unbiased population-based prospective studies are needed to investigate the association between GAD and cancer risk.
Conceived and designed the experiments: CCS LYH. Analyzed the data: CCS YWH CJL. Contributed reagents/materials/analysis tools: MHH

References

1. Wittchen HU (2002) Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16: 162–171.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, et al. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8–19.
3. Karmo M, Golding JM, Sorenson SB, Burnam MA (1988) The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45: 1094–1099.
4. Carter RM, Wittchen HU, Pfister H, Kessler RC (2001) One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample: Depress Anxiety 15: 78–86.
5. Halápy EB, Szilágyi DV (2012) Generalized anxiety disorder. Handb Clin Neurol 106: 343–362.
6. Masson AO, Warshaw MG, Keller MB (1995) Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 150: 600–607.
7. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC (2000) Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 15: 319–326.
8. Kayano H, Koba S, Matsui T, Fukuoka H, Toshida T, et al. (2012) Anxiety disorder is associated with nocturnal and early morning hypertension with or without morning surge. Curr J 76: 1670–1677.
9. Hornstein C (2004) Stress, anxiety and cardiovascular disease: an inter disciplinary approach. Vertex 15 Suppl 1: 21–31.
10. Guimondsson G, Gislason T, Janson C, Lindberg E, Suppli Ulrik C, et al. (2006) Depression, anxiety and health status after hospitalisation for COPD: a multicentre study in the Nordic countries. Respir Med 100: 87–93.
11. Mousas G, Tselios A, Karanikas A, Stamos D, Elias I, et al. (2008) A comparative study of anxiety and depression in patients with bronchial asthma, chronic obstructive pulmonary disease and tuberculosis in a general hospital of chest diseases. Ann Gen Psychiatry 7: 7.
12. Rovira J, Albaraccin G, Salvador L, Rejas J, Sanchez-Isreto E, et al. (2012) The cost of generalized anxiety disorder in primary care settings: results of the ANCOROA study. Community Ment Health J 48: 372–383.
13. Hamer M, Chida Y, Molloy GJ (2009) Psychological distress and cancer mortality. J Psychosom Res 66: 255–258.
14. Chida Y, Hamer M, Wardle J, Steptoe A (2008) Do stress-related psychological factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 5: 466–475.
15. Schraub S, Sanchez-Garmier H, Velmuth M (2009) Should psychological events be considered cancer risk factors? Rev Epidemiol Sante Publique 57: 113–123.
16. Schwarz S, Messerschmidt H, Doren M (2007) Psychosocial risk factors for cancer development. Med Klin (Munich) 102: 967–978.
17. Nielsen NR, Grobbecke M (2006) Stress and breast cancer: a systematic update on the current knowledge. Nat Clin Pract Oncol 3: 612–620.
18. Kruk J, Aoubine-Eyni HY (2004) Psychological stress and the risk of breast cancer: a case-control study. Cancer Detect Prev 28: 399–408.
19. Lillingr K, Verkosalu PK, Kaprio J, Teppro I, Helenius H, et al. (2003) Stressful life events and risk of breast cancer in 10,800 women: a cohort study. Am J Epidemiol 157: 415–423.
20. Liang JA, Sun LM, Su KP, Chang SN, Sung FC, et al. (2012) A nationwide population-based cohort study: will anxiety disorders increase subsequent cancer risk? PLoS One 7:e63707.
21. Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Flint J (2007) Cancer in people with depression or anxiety: record-linkage study. Soc Psychiatry Psychiatr Epidemiol 42: 683–689.
22. Aro AR, De Koning HJ, Schreck M, Henriksson M, Anttila A, et al. (2005) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6: 240–248.
23. Yang EV, Glaeser R (2003) Stress-induced immunomodulation: Implications for tumorigenesis. Brain Behav Immun 17 Suppl 1: S37–40.
24. Sephton S, Spiegel D (2005) Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 17: 321–328.
25. Ou SM, Lee YJ, Hu YW, Liu CJ, Chen TJ, et al. (2012) Does Alzheimer’s Disease Protect against Cancers? A Nationwide Population-Based Study. PLoS One 7:e57399.
26. Liang JA, Sun LM, Su KP, Chang SN, Sung FC, et al. (2012) Gender and cancer. Lancet Oncol 13: 617–625.
27. Reiche EM, Morimoto HK, Nunes SM (2005) Stress and depression-induced immune dysfunction: implications for the development and progression of cancer. Int Rev Psychiatry 17: 513–527.
28. Reiche EM, Nunes SM, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5: 617–625.
29. Antoni MH, Latgentord SK, Cole SW, Dhahb F, Sephson SE, et al. (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6: 240–248.